Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Biotech
Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific
Pfizer has bagged ex-China rights, establishing itself as a challenger to BioNTech, Merck and Summit in a scorching-hot area of immuno-oncology.
Nick Paul Taylor
May 20, 2025 4:47am
GSK axes $625M TIGIT drug as midphase data disappoint
May 13, 2025 9:44am
Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3
Apr 28, 2025 7:25am
Apollomics tags out of TYG oncology pact to cut costs
Apr 4, 2025 6:45am
BioNTech posts survival data behind bispecific's phase 3 push
Mar 28, 2025 8:00am
ImmuneOnco axes CD47 bispecific amid pipeline prioritization
Mar 26, 2025 6:21am
